TD Asset Management’s ADMA Biologics ADMA Stock Holding History

TD Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-56,852	Closed	-$1.04M	–	1237
2025 Q2	$1.04M	Buy	+56,852	New	+$1.16M	﹤0.01%	1053

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SHCM

Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TD Asset Management's ADMA Position: Q3 2025 in Review

TD Asset Management sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 56,852 shares — an estimated $1.04M sold.

TD Asset Management first reported a position in ADMA in Q2 2025 and held it in 1 quarter. The position peaked at $1.04M in Q2 2025. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

TD Asset Management reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
TD Asset Management sold 56,852 ADMA Biologics shares in Q3 2025, an estimated $1.04M.
TD Asset Management first reported a position in ADMA Biologics in Q2 2025 and held it in 1 quarter.
TD Asset Management's ADMA Biologics position peaked at $1.04M in Q2 2025.
365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on TD Asset Management's 13F filing for Q3 2025, filed 10 Nov 2025.